TrachFlush Distribution Deal Reached for Japan

AW Technologies and Asahi Kasei Medical have forged an exclusive distribution agreement in Japan for the former’s TrachFlush device. AW Technologies is currently registering TrachFlush in Japan and plans to launch the product in fiscal 2024.

“We are pleased and excited to announce our partnership with Asahi Kasei Medical. This partnership is very important for AW Technologies, and Asahi Kasei Medical will play a very important role in our expansion of TrachFlush globally,” AW Technologies CEO Adam Hansen said. “We believe the TrachFlush will have a great impact in the ICU—not only by preventing ventilator-associated pneumonia, but also by non-invasively preventing the accumulation of secretion in the airways.”
 
Developed by AW Technologies based on an invention by an intensivist, the TrachFlush is designed to reduce the discomfort of ventilated patients while lightening the workload on healthcare professionals during tracheal suctioning. The TrachFlush supports airway secretion (phlegm) management with a unique cuff pressure control system, and has received the CE Mark in Europe in 2020 and U.S. Food and Drug Administration clearance in the United States in 2023. In Japan, marketing and sales is to be performed by Asahi Kasei Medical.
 
With the push of a button, the TrachFlush deflates the cuff and utilizes the ventilator air pressure during an inspiratory cycle, and re-inflates the cuff before the cycle completes.
 
“We are delighted to add the TrachFlush to our product lineup in the intensive care field, where we have strength in the area of blood purification. By leveraging our experience and know-how in blood purification, we believe that this will deliver diverse value, such as enhancing patients’ QOL and reducing the burden on healthcare workers,” Asahi Kasei Medical President Ken Shinomiya stated.

AW Technologies is a Danish medical device company, established in 2018, focused on developing airway management solutions for mechanically ventilated ICU patients.
 
The Asahi Kasei Group, founded in 1922, employs more than 48,000 workers worldwide through its three business sectors—Material, Homes, and Health Care. Asahi Kasei Medical is a core operating company in the Health Care sector. Its blood purification business comprises devices and systems for dialysis and therapeutic apheresis, and its bioprocess business comprises equipment for the manufacture of biotherapeutics, biosafety testing services, and biologics CDMO operations.